BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)BB

BIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)

11.500USDD
+0.450+4.07%
At close at Feb 25, 17:39 GMT
USD
No trades
See on Supercharts

BIIBD fundamentals

Key facts

Market capitalization‪20.47 B‬USD
Founded1978
Employees (FY)‪7.61 K‬
CEOChristopher A. Viehbacher
Websitebiogen.com
About

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪20.47 B‬‬
Price to earning ratio (P/E)
15.07x
Price to sales ratio (P/S)
2.62x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
15.07x
Price to sales ratio (P/S)
2.62x
Valuation ratios
‪0.00‬
‪3.50‬
‪7.00‬
‪10.50‬
‪14.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪35.00‬
‪70.00‬
‪105.00‬
‪140.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10%‬
‪14%‬
‪18%‬
‪22%‬
‪26%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪600.00 M‬‬
‪‪1.20 B‬‬
‪‪1.80 B‬‬
‪‪2.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Innovative Therapies
By country
Period: 2024
United States
Europe
Germany
Asia
Other

Dividends

Dividend yield, history and sustainability

BIIBD does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−2.50 B‬‬
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
‪‪24.00 B‬‬
Assets
Liabilities